2024 SABCS Poster: Epigenomic Characterization of ER Transcriptional Activation via Liquid Biopsy

Multimodal Oncology Pipeline Targeting B7-H7- Positive Patients at Piper Sandler 36th Annual Healthcare Conference

2024 AACR LBx Poster-Determination of tumor PSMA expression and response Lutetium-PSMA in men with prostate cancer using a novel epigenomic liquid biopsy platform

Nextpoint Therapeutics to Participate in Stifel Healthcare Conference

Poster Presentation on a B7-H7 Directed T Cell Engager Therapy at SITC2024

Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases

Leerink Partners Biopharma Private Company Connect

Precede Biosciences Presents Data on Liquid Biopsy Comprehensive Epigenomic Profiling of MS Patients at ECTRIMS 2024

Poster- A Novel Comprehensive Epigenomic Liquid Biopsy Assay Reveals Disease Biology in Multiple Sclerosis Patients from 1mL of Plasma

Comprehensive Epigenomic Profiling from Plasma Inform Drug Development, Cancer Biology, and Therapy Selection

2024 ESMO Poster: Determination of tumor PSMA expression in prostate cancer from blood using a novel epigenomic liquid biopsy platform

Precede Biosciences Presents New Data at ESMO 2024 Demonstrating Ability Reveal Tumor PSMA Expression from a Simple Blood Test that is Highly Correlated with PSMA-PET Imaging

First-in-class T Cell Engager NPX372 As New Drug Candidate Targeting B7-H7 in Solid Tumors

Neomorph Announces Appointment of Dr. Peter Lebowitz, M.D., Ph.D. to its Board of Directors

Predicta Biosciences Secures $5.2M to Transform the Diagnosis, Treatment and Monitoring of Blood Cancers

This Start-up Raised $5.2M to Develop Blood Tests for Cancer